Introduction
Pathological mechanisms involved in multiple sclerosis (MS) MS is a chronic demyelinating disease of the central nervous system (CNS). Oligodendrocytes, the myelin-forming cells of the CNS, are target cells in the pathogenesis of MS. At present the cause of onset of MS is unknown, but activated T cells and macrophages are thought to be involved in demyelination through various mechanisms. New insights suggest oligodendrocyte apoptosis to be a primary event accompanied by microglial activation (Barnett & Prineas, 2004) . Subsequently, T cells and macrophages become activated and migrate into the lesion area. The important pathological mechanisms involved in MS include immunemediated inflammation (Owens, 2003) , oxidative stress (Evans, 1993; Knight, 1997; Smith et al, 1999) and excitotoxicity (Matute et al, 2001) . These mechanisms may all contribute to oligodendrocyte and neuronal damage and even cell death, hence promoting disease progression.
Immune-mediated inflammation. MS has an autoimmune inflammatory component mediated by myelin-specific CD4 þ T cells. However, recent studies have challenged this concept by indicating a role for other immune cells (Hemmer et al, 2002) . Recently, axonal damage has been identified as an early hallmark of MS (Kornek & Lassmann, 2003) involving CD8 þ T cells and antibodies (Owens, 2003) .
Inflammatory cells and mediators induce axonal loss as well as demyelination. In contrast, inflammation may improve MS pathology (Kieseier & Hartung, 2003) . As different immunopathological pathways are involved in different subgroups of patients (Lassmann, 1999; Kornek & Lassmann, 2003) , the specific role of antioxidants and polyunsaturated fatty acids (PUFAs) deserves further clarification.
Oxidative stress. Reactive oxygen species (ROS) are implicated as mediators of demyelination and axonal damage in both MS and experimental allergic encephalomyelitis (EAE) (Lin et al, 1993; Cross et al, 1997; van der Goes et al, 1998) , an animal model of MS. Local ROS levels increase dramatically under inflammatory conditions and exhaust the antioxidant defence potential within the lesions (Smith et al, 1999) . These excessive ROS levels are primarily generated by activated macrophages and microglia (Fisher et al, 1988; Hartung et al, 1992) . ROS can damage lipids, proteins and nucleic acids of cells, resulting in disturbed mitochondrial function which may induce cell death (Bolanos et al, 1997; Merrill & Scolding, 1999) . Oligodendrocytes, including the extensive myelin sheaths they produce, are particularly vulnerable to oxidative stress (Smith et al, 1999) . Oxidative stress in vivo can selectively cause oligodendrocyte cell death, resulting in demyelination. ROS may also damage the myelin sheath by promoting its attack by macrophages (van der Goes et al, 1998) . Furthermore, oxidative stress is involved in the cascade of events leading to neuronal cell death (Emerit et al, 2004) .
Excitotoxicity. Oligodendrocytes are highly vulnerable to excitotoxic signals mediated by glutamate receptors (Oka et al, 1993; Matute et al, 2001) . During inflammation, activated immune cells release large amounts of glutamate (Piani & Fontana, 1994) . Oligodendrocytes contribute to the CNS glutamate homeostasis by means of their own transporters. However, alterations in glutamate homeostasis can result in overactivation of glutamate receptors and subsequent excitotoxic oligodendroglial death (Matute et al, 2001) . Demyelinated lesions caused by excitotoxins can be similar to those observed in MS, and glutamate-induced excitotoxicity may cause axonal loss. Together with the beneficial effects of glutamate receptor antagonists in EAE, these findings indicate that oligodendrocyte excitotoxicity plays a role in the pathogenesis of MS (Pitt et al, 2000) .
Interaction between different pathological mechanisms in MS
In CNS disease oxidative stress has been linked with other pathogenic mechanisms such as excitotoxicity (Léwen et al, 2000) . High levels of extracellular glutamate inhibit the cellular availability of cystine. This results in the depletion of glutathione and induces a form of cell injury called oxidative glutamate toxicity (Schubert & Piasecki, 2001 ). Excitotoxicity frequently leads to a prooxidant condition. Both excitotoxic and 'oxidotoxic' states result from the failure of normal compensatory antiexcitatory and antioxidative mechanisms to maintain cellular homeostasis (Bondy & LeBel, 1993) . Furthermore, oxidative toxicity and excitotoxicity are closely interactive and excitotoxicity likely constitutes the final common pathway of neuronal and axonal loss (Lipton & Rosenberg, 1994) .
Treatment strategies in MS
Remyelination occurs during the early phases of disease, whereas this is rare at more progressed stages (Lassmann et al, 1997) . Remyelination requires the presence of oligodendrocyte progenitors in the vicinity of the lesion area and involves adequate control by specific growth factors (Woodruff & Franklin, 1997) . Differentiation of progenitors into mature myelin-forming oligodendrocytes is accompanied by extensive formation of new oligodendrocyte cell membranes to re-insulate demyelinated axons. It is suggested that dietary compounds such as PUFAs may support this process (Di Biase & Salvati, 1997) . At present, no pharmaceutical or other therapy exists that can confer prolonged remission in MS and therapeutic agents are only partially effective. Their long-term beneficial effects are uncertain and often detrimental side-effects have been reported (Johnson et al, 1995; Filippini et al, 2003) . This review addresses the role of nutrition in MS. We discuss the potential of directly acting nonenzymatic antioxidants for dietary supplementation and elaborate on the role of longchain n-6 and n-3 PUFAs in immunosuppression, cellular function and remyelination.
Role of nutrition in MS
Correlation of dietary pattern with the incidence of MS The etiology of MS is largely unknown, although genetic and environmental factors are believed to be involved. Diet is an important subject of etiologic research in this respect. Swank (1950) found a correlation between high dietary intake of saturated fatty acids and the incidence of MS. Meta-analysis of epidemiological studies has demonstrated a relation between MS mortality and dietary fat (Esparza et al, 1995) . Saturated fatty acids, animal fat and animal fat without fish fat correlate positively with MS mortality. An increased risk for MS was found to be associated with high energy and animal food intake (Ghadirian et al, 1998) . The same study also revealed a protective effect of other nutrients, including vegetable protein, dietary fibre, cereal fibre, vitamin C, thiamine, riboflavin, calcium and potassium. In contrast, another study found no associations between intake of fruits and vegetables, multivitamins and vitamins C and E, with the risk of MS in women (Zhang et al, 2001) .
Antioxidant deficiencies in MS
It is not clear at present if antioxidant deficiency in MS is constitutive or due to excessive antioxidant consumption to cope with oxidative stress. Antioxidant deficiencies may develop during the course of MS as a result of chronic inflammation that is accompanied by increased oxidative stress. Levels of the antioxidants a-tocopherol, b-carotene, retinol and ascorbic acid were decreased in the sera of MS patients during an attack (Besler et al, 2002) . This was also illustrated by increased oxidative burden, as reflected by lipid peroxidation. Another study showed lipoprotein oxidation being an important sign of oxidative stress during the course of MS. Therefore, in vitro measurements of plasma oxidation kinetics as an indication for lipoprotein oxidation may be an additional tool in the clinical diagnosis of MS (Besler & Comoglu, 2003) .
The chemical composition of human cerebrospinal fluid (CSF) is considered to reflect brain metabolism. CSF vitamin E levels were not significantly different between MS patients during exacerbations as compared to controls, while serum levels of vitamin E indeed were lower in MS patients (Jimenez-Jimenez et al, 1998) . In MS plaques, levels of glutathione (GSH) and vitamin E were significantly decreased as compared to adjacent and distant white matter (Langemann et al, 1992) . From these studies, it can be concluded that systemic, CSF and brain tissue levels of several antioxidants indeed are altered in MS. Therefore, antioxidant therapy may be beneficial in restoring these deficiencies and supporting the antioxidant defence capacity of MS patients.
PUFA deficiencies in MS
In a double-blind and randomised study, no differences were observed between MS patients and healthy controls with regard to fat malabsorption (Wong et al, 1993) . Nevertheless, there were deficiencies of essential PUFAs (ie PUFAs of the n-3 and n-6 series; Figure 1 ) in both plasma lipids and erythrocytes (Cherayil, 1984; Cunnane et al, 1989; Holman et al, 1989) . Plasma linoleic acid (LA; 18:2n-6) was normal, and g-linolenic acid (GLA; 18:3n-6) increased in MS patients, but subsequent n-6 acids were subnormal, indicating impairment of chain elongation (Holman et al, 1989) . In addition, the content of all n-3 fatty acids was subnormal and PUFA deficiency was compensated mass-wise by an increase in saturated fatty acids. In red blood cells and adipose tissue of mild inactive MS patients, there was a significant reduction in eicosapentaenoic acid (EPA; 20:5n-3), and an increase in both dihomo-g-linolenic acid (DGLA; 20:3n-6) and stearidonic acid (SA; 18:4n-3) (Nightingale et al, 1990) . In contrast, there were no detectable EPA levels in the adipose tissue of MS patients and healthy individuals. However, whereas in MS patients docosahexaenoic acid (DHA; 22:6n-3) was not detectable, 40% of healthy controls had significant levels varying from 0.1 to 0.3% of the total estimated fatty acid. No reduction in LA was observed in red blood cells or adipose tissue of MS patients (Nightingale et al, 1990) . In MS plaques, the lipid and fatty acid composition appears to be altered (Wilson & Tocher, 1991) . The cause of these PUFA deficiencies is not entirely clear and may involve metabolic and nutritional alterations.
Intervention studies
The effect of PUFA supplementation in MS has extensively been investigated, but with equivocal outcome. The evaluation of three double-blind trials with LA (n-6) in early MS showed reduction of the severity and duration of relapses (Dworkin et al, 1984) . Fish oil supplemented together with vitamins and dietary counselling improved the clinical outcome in newly diagnosed MS patients (Nordvik et al, 2000) . On the other hand, a clinical trial with n-3 PUFA treatment in acute relapsing MS showed no significant differences (Bates et al, 1989) . However, there was a favourable trend of the n-3 PUFAs-treated group on parameters like overall deterioration, as well as the frequency, severity and duration of relapses. The discrepancies between these studies may be explained by different criteria for patient selection (clinical subtype of MS), and different disability scores at the start of the study (Gallai et al, 1992) .
High-dose antioxidant supplementation with sodium selenite, vitamin C and vitamin E has been tested in MS patients and appeared to be safe (Mai et al, 1990) . Moreover, low blood GSH peroxidase activity that was associated with disease activity could be increased by the antioxidant administration (Mai et al, 1990) . Similarly, antioxidant treatment with selenium, vitamin C and E restored GSH levels as well as the GSH peroxidase activity in erythrocytes of MS patients (Jensen & Clausen, 1986) .
Oxidative stress and antioxidants
Reactive oxygen and nitrogen species ROS and reactive nitrogen species (RNS) play an important role during the pathogenesis of MS. ROS are produced primarily by mitochondria as a by-product of normal cell metabolism during conversion of molecular oxygen (O 2 ) ( Figure 2 ). The products formed by the mitochondrial Figure 1 Metabolic pathways of desaturation and elongation of n-6 and n-3 fatty acids. The different families of fatty acids may compete in the desaturation process. n-6 and n-3 fatty acids in phospholipids are precursors of prostaglandin E (PGEx) synthesis. LA, linoleic acid; GLA, g-linolenic acid; DGLA, dihomo-g-linolenic acid; AA, arachidonic acid; DTA, docosatetraenoic acid; DPA, docosapentaenoic acid; LNA, a-linolenic acid; SA, stearidonic acid; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid.
respiratory chain include superoxide radical (O 2 ÀK ), hydrogen peroxide (H 2 O 2 ) and hydroxyl radical (HO K ). Transfer of an electron to oxygen by cytochrome c oxidase and flavin enzymes results in production of O 2 ÀK (Léwen et al, 2000) . 
. Peroxynitrite decays to yield oxidising and nitrating species that react in complex ways with different relevant biomolecules. These reactive species not only induce lipid peroxidation or affect DNA structure, they also react with cellular proteins by tyrosine nitration (Smith et al, 1999; Torreilles et al, 1999 (Figure 2 ). Under certain conditions, formation of HO K will be perpetuated through the nonenzymatic Haber-Weiss reaction, requiring free intracellular iron and O 2 ÀK or ascorbate (Halliwell, 1992) .
Antioxidant treatment in experimental models of MS Activated macrophages and microglia may produce high levels of NO and H 2 O 2 that are involved in the pathogenesis of EAE (Lin et al, 1993; Ruuls et al, 1995; Minghetti & Levi, 1998) . Treatment of EAE with catalase, a H 2 O 2 scavenger, markedly suppressed disease severity (Ruuls et al, 1995) . In the same model, local augmentation of catalase by viralmediated gene delivery suppressed optic neuritis (Guy et al, 1998) . In contrast, intraperitoneal administration of SOD, an enzyme that detoxifies superoxide, had no effect in EAE in rats (Ruuls et al, 1995) . Uric acid is a natural scavenger of peroxynitrite that inhibits clinical signs in EAE and MS patients (Hooper et al, 1998) . Evaluation of more than 20 million patient records revealed MS and gout (hyperuricemic syndrome) to be mutually exclusive diseases, suggesting hyperuricaemia to protect against MS (Hooper et al, 1998; Spitsin et al, 2002) . Furthermore, oral administration of the oxidant scavenger N-acetylcysteine (NAC) inhibited EAE (Lehmann et al, 1994) . Desferrioxamine, an iron chelator (Pedchenko & LeVine, 1998) , suppressed the development of EAE, whereas iron-deficient mice failed to develop EAE (Grant et al, 2003) . It was proposed that the mechanism of EAE inhibition in iron-deficient mice involves the delivery and metabolism of iron for optimal CD4 þ T-cell development (Grant et al, 2003) . Some investigators have shown iNOS inhibition as well as NO scavenging to suppress EAE (Cross et al, 1994; Zhao et al, 1996; Hooper et al, 1997; Jolivalt et al, 2003) , whereas others have shown iNOS inhibition (O'Brien et al, 1999 (O'Brien et al, , 2001 or NO donor (Xu et al, 2001 ) to aggravate or ameliorate EAE, thus not clarifying the exact role for NO .
Cellular antioxidant defence
The cellular antioxidant defence mechanisms can be classified into two major groups: enzymatic (eg, catalase, SOD, hydrogen peroxidase), and nonenzymatic or low-molecularweight antioxidants . The latter group can be further classified into directly acting antioxidants (eg, scavengers and chain breaking antioxidants) and indirectly acting antioxidants (eg, chelating agents). This review focussed on directly acting nonenzymatic antioxidants, for example, vitamin C and E, thiol-based antioxidants, flavonoids and curcumin.
Vitamin C. Vitamin C (ascorbic acid) is a water-soluble antioxidant found throughout the body as the ascorbate anion. Ascorbate is abundantly present in the CNS. Humans have lost the ability to synthesise ascorbate, but dietary sources like fruit and vegetables are widely available and ascorbate is readily absorbed from the gut (Kallner et al, 1977 ). The high intracellular ascorbate level in the CNS underlines its important function. Ascorbate is part of the brain antioxidant network (Figure 3 ) and acts as an intracellular antioxidant in the defence against highly reactive free radicals (Cohen, 1994) . Ascorbate operates in concert with other low-molecular-weight molecules, including GSH and vitamin E, as well as with antioxidant enzymes such as SOD and GSH peroxidase (Cohen, 1994) .
Ascorbate concentrations in plasma are about 50 mM (Hornig, 1975) , while the concentration in neurons is estimated to be 10 mM and levels of 1 mM in glia (Rice & Russo-Menna, 1998) . The brain has a relative high rate of oxidative metabolic activity and low levels of protective antioxidant enzymes, for example, catalase and GSH peroxidase (Evans, 1993) . Under normal physiological conditions, oxidation of ascorbate into dehydroascorbate can be reduced by GSH. In this way, ascorbate is continuously regenerated. However, when high levels of ROS are produced, oxidative stress will occur in the context of insufficient antioxidative capacity to regenerate ascorbate. During active disease in MS, ROS scavenging by ascorbate and other molecules of the antioxidant network might deplete levels of these defence molecules (Besler et al, 2002) .
Vitamin C can also increase iron-catalysed oxidation through the Fenton reaction, generating hydroxyl radicals (Nappi & Vass, 1997) that are very reactive and detrimental to various cell structures by oxidation of DNA, RNA, proteins and membrane lipids (Richter et al, 1988; Halliwell, 1992) . Vitamin C treatment was not found to be protective in murine EAE and the authors explained this by the ambivalent role of vitamin C during oxidative stress (Spitsin et al, 2002) . The latter should be taken into account when vitamin C supplementation to MS patients is considered.
Vitamin E. Where ascorbate is predominantly found in the cytosol, vitamin E is localised exclusively within the lipid part of cell membranes (Figure 3) . Vitamin E is an important antioxidant that can interrupt the propagation of free radical chain reactions (Vatassery, 1998a) . Vitamin E occurs in at least eight different isoforms: a-, b-, g-and d-tocopherols and a-, b-, g-and d-tocotrienols. Although the antioxidant activity of tocotrienols is higher than that of tocopherols, tocotrienols have a lower bioavailability after oral ingestion (Packer et al, 2001) . Vitamin E can be found in our diet in vegetable oils like sunflower and olive oil, non-citrus fruits, nuts and seeds. It is absorbed together with lipids in the intestine and released into the circulation through chylomicrons.
In contrast to vitamin C, levels of vitamin E in the brain are not remarkably different from those in other organs (Vatassery, 1998a) . Vitamin E levels in the CSF are about 1000 times lower as compared to serum levels as a consequence of the low lipid concentration in the CSF, which is o0.2% of the concentration in serum (Vatassery et al, 1991) . In the blood of MS patients, a-tocopherol levels are lowered during exacerbation (Karg et al, 1999; Besler et al, 2002) , whereas a-tocopherol levels in CSF during MS exacerbation are not different from controls (JimenezJimenez et al, 1998) .
Vitamin C and E work closely together in the antioxidant network at the interface of cytosol and cell membrane, where oxidised vitamin E can be regenerated by vitamin C Figure 3 The antioxidant network showing the interaction between vitamin E, vitamin C and thiol redox cycles, as well as their cellular localisation; adapted from Packer et al (2001) . ROS and products of lipid peroxidation present in the cytosol or cell membrane may be detoxified by this system. ROO K , peroxyl radical; RO K , alkoxyl radical. (Vatassery, 1998a) (Figure 3 ). Rare genetic mutations may lead to vitamin E deficiencies, whereas vitamin E deficiency due to dietary restriction has not been reported in humans (Brigelius-Flohe et al, 2002) . The antioxidant efficiency of a-tocopherol depends on its ability to react mainly with the chain-initiating or chain-propagating lipid radicals during lipid peroxidation (Fukuzawa et al, 1985) . Furthermore, atocopherol efficiently detoxifies hydroxyl, perhydroxyl and superoxide free radicals (Fukuzawa & Gebicki, 1983) . aTocopherol has been demonstrated to protect rat brain subcellular fractions against peroxynitrite-induced oxidative damage (Vatassery et al, 1998b) . However, g-tocopherol seems to be more effective than a-tocopherol in trapping NO radicals (Christen et al, 1997) . This discrepancy in activity may be related to their structural properties. aTocopherol also exerts non-antioxidant properties, for example, modulation of cell signalling, regulation of transcription, modulation of immune function and induction of apoptosis (Brigelius-Flohe et al, 2002) . Taken together, vitamin E isoforms are important in the protection of CNS cells through antioxidative and nonantioxidative mechanisms. However, it is difficult to achieve high plasma atocopherol concentrations irrespective of the amount or duration of dietary supplementation (Dimitrov et al, 1991) . In addition, feeding studies in healthy mice revealed a tissuespecific distribution of tocopherols and tocotrienols. Brain vitamin E contained only a-tocopherol and traces of g-tocopherol, where a-and g-tocotrienols were both undetectable, suggesting a specific transport mechanism for a-tocopherol to cross the blood-brain barrier (BBB) (Podda et al, 1996) .
Thiol-based antioxidants N-acetylcysteine (NAC). NAC belongs to the group of thiol-based antioxidants, which also includes a-lipoic acid and GSH (Deneke, 2000) . It is widely used as a drug because of its ability to scavenge H 2 O 2 , hydroxyl radicals and hypochlorus acid, and it acts as a precursor for GSH synthesis (Wernerman & Hammarqvist, 1999) . NAC may increase intracellular cysteine and subsequent GSH levels (Deneke, 2000) . The molecular mechanism of NAC was recently reviewed (Zafarullah et al, 2003) . NAC affects transcription factors, apoptosis and cell survival, all of which are important targets in treating neurodegenerative diseases.
Clinical use of NAC has shown replenishment of GSH levels in HIV-positive (Herzenberg et al, 1997) and cystic fibrosis patients (Meyer et al, 1995) . NAC usage has been suggested for neurodegenerative disorders like Alzheimer's disease or Parkinson's disease (Deigner et al, 2000) , but there are no clinical studies supporting its use in MS. Interestingly, oral administration of NAC did inhibit acute EAE in mice (Lehmann et al, 1994) and recent data revealed that NAC amide protects against EAE by scavenging ROS and reducing matrix metalloproteinase-9 (MMP-9) activity .
In vitro data have shown that cultured oligodendrocytes were protected against tumor necrosis factor (TNF)-ainduced toxicity by NAC (Cammer, 2002) . In addition, treatment with NAC partially suppressed virus-stimulated production of NO and TNF-a by astrocytes (Molina-Holgado et al, 1999), and NAC has been shown to protect neuronal cells from apoptosis (Deigner et al, 2000) . NAC inhibited TNF-a-mediated apoptosis in rat primary oligodendrocytes by increasing intracellular GSH levels and inhibited NO production in lipopolysaccharide-stimulated macrophages, C6 glial cells and primary astrocytes .
Glutathione. GSH has important intracellular antioxidant defence and scavenging capacities, and can be found in millimolar concentrations in most tissues (Wernerman & Hammarqvist, 1999) . In contrast to ascorbate, which is highly concentrated in neurons, GSH is localised preferentially in glia cells (Rice & Russo-Menna, 1998) . GSH can act as a cofactor for the enzymatic GSH peroxidase reaction by which cells convert H 2 O 2 or lipid peroxides to the less toxic H 2 O or lipid hydroxyl compounds. Oxidised GSH (GSSG), a product of this reaction, is then recycled into GSH by GSH reductase. GSH can also react directly with oxidants and other radicals (Deneke, 2000) (Figure 3) .
In MS patients, during exacerbation blood levels of oxidised GSH were elevated, while levels of reduced GSH were increased during exacerbation and remission (Karg et al, 1999) . This could reflect a compensatory mechanism to defend cells against oxidative stress. In another study, decreased levels of GSH were measured in plaques from MS patients (Langemann et al, 1992) . Moreover, decrease of reduced GSH and increase oxidised GSH and S-nitrosothiols were found in CSF samples of MS patients (Calabrese et al, 2002) . Oral administration of GSH results in poor systemic bioavailability (Kidd, 2001) . Therefore, NAC supplementation seems preferable in a low GSH status since this compound has superior bioavailability. It should be noted that restoring GSH levels via NAC supplementation could be less effective in case GSH peroxidase enzyme activity is impaired. The latter has been described in blood-derived lymphocytes and erythrocytes from MS patients (Jensen & Clausen, 1986; Mai et al, 1990 ). a-Lipoic acid. a-Lipoic acid and its reduced form dihydrolipoic acid (DHLA) are thiol-based antioxidants. Meat is an important source of a-lipoic acid, which is absorbed from the gastrointestinal tract (Harrison & McCormick, 1974) , but can also be synthesised (Carreau, 1979) . a-Lipoic acid can interfere with lipid peroxidation by competing for free transition metals as a chelator (Muller & Menzel, 1990) and by scavenging hydroxyl radicals (Suzuki et al, 1991) . On the other hand, DHLA can scavenge peroxyl radicals (Kagan et al, 1992) . Both compounds are capable of scavenging superoxide radicals (Suzuki et al, 1991) and are integrated in the antioxidant network (Figure 3) . DHLA is capable of reducing GSSG to GSH and can regenerate ascorbate, either by direct reaction with dehydroascorbate or through reduction of GSSG to GSH, which is also a reducing agent for ascorbate (Packer et al, 1995) .
The beneficial effects of a-lipoic acid in EAE were associated with its nonantioxidative capacity (Morini et al, 2004) . Furthermore, a-lipoic acid was effective in treating EAE by inhibiting T-cell trafficking into the spinal cord by inhibiting matrix metalloproteinase activation (Marracci et al, 2002) . Furthermore, it has been precised that a-lipoic acid, like NAC , reduces MMP-9 activity, whereas DHLA does not (Marracci et al, 2004) .
The antioxidant capacity of a-lipoic acid was also tested in vitro on OLN-93 oligodendroglia. a-Lipoic acid elevated cell viability and decreased protein oxidation after H 2 O 2 -induced oxidative stress (Ernst et al, 2004) . Myelin phagocytosis by macrophages, which is a ROS-mediated process and an important immunological event in MS pathology, could also be decreased by a-lipoic acid (van der Goes et al, 1998).
Considering the above, NAC, a-lipoic acid and DHLA might prevent ROS-induced CNS demyelination and axonal damage in MS patients. However, the relevance of thiol-based dietary supplementation and their potential role in antioxidant therapy for MS patients remains to be established.
Flavonoids. Flavonoids belong to a group of at least 4000 naturally occurring compounds found in fruit, vegetables, grains, tea and wine (Manach et al, 2004) . Flavonoids share a common polyphenolic structure consisting of two aromatic rings that are bound together by three carbon atoms that form an oxygenated heterocycle. There are six different subclasses of flavonoids depending on the type of heterocycle involved: flavonols, flavones, isoflavones, flavanones, anthocyanidins and flavanols.
The health effects of polyphenols depend on intake and bioavailability (Manach et al, 2004) . By using the data of the Dutch National Food Consumption Survey 1987 Survey -1988 , the daily human intake of a subset of five anticarcinogenic flavonoids was estimated to be around 23 mg/day (Hertog et al, 1993) . The intake of those antioxidant flavonoids still exceeded that of the antioxidants b-carotene and vitamin E. Thus, flavonoids seem to represent an important source of antioxidants in the human diet.
Flavonoids derived from natural sources occur mainly as glycosides, that is, covalent binding of a sugar moiety to the aglycon. The glycoside forms of the flavonoid quercetin are more readily absorbed from the intestine than its aglycon (Hollman & Katan, 1998) . Owing to their hydrophilicity, flavonoids are likely to be concentrated at the interface between the phospholipid bilayers and cytosol, where they can prevent lipid peroxidation. Over the years, flavonoids have appeared to be safe dietary compounds with a broad range of biological activities (Middleton et al, 2000) .
The strong antioxidant activity of flavonoids is attributed to the polyphenolic molecular structure and depends on their interaction with the cell membrane (Saija et al, 1995) . Flavonoids can prevent oxidative stress by direct scavenging of free radicals. In this way, flavonoids become oxidised and form a more stable and less reactive radical. Luteolin and quercetin belong to the flavone and flavonol group, respectively, and both prevent H 2 O 2 -induced oxidative stress in oligodendroglia (van Meeteren et al, 2004) . Some flavonoids, for example, quercetin, can redoxcycle (Hodnick et al, 1986) and have been shown to be pro-oxidants by the reduction of Fe 3 þ (Canada et al, 1990) . This renders these compounds less suitable for therapeutical application (van Acker et al, 1996) . Flavonoids are also very potent NO radical scavengers (van Acker et al, 1995) and inhibit the NO production by activated macrophages (van Meeteren et al, 2004) , microglia (Merrill et al, 1993) and astrocytes (Soliman & Mazzio, 1998) . Flavonoids act at other cellular levels, for example, inhibition of iNOS enzyme activity (Kobuchi et al, 1999) , iNOS protein expression (Kim et al, 1999; Liang et al, 1999; van Meeteren et al, 2004) and transcription of nuclear factor kB (NFkB) (Choi et al, 2003) . Interactions between flavonoids and the antioxidant network have been described. Flavonoids may spare ascorbate from oxidation by metal chelation or by free radical scavenging (Kandaswami & Middleton, 1994) .
Some flavones and flavonols such as apigenin, kaempferol and naringenin can have estrogenic effects (Miksicek, 1995) , whereas others exert antiestrogenic properties (Virgili et al, 2004) . Based on the observation that MS patients have fewer relapses during pregnancy and that the disease is commonly exacerbated in the first few months after delivery, estrogen has been suggested to ameliorate disease progression (Confavreux et al, 1998) . In addition, oral administration of estrogen suppressed clinical symptoms in murine EAE and inhibited the recruitment of inflammatory cells into the CNS (Subramanian et al, 2003) . Interestingly, a recent report by Muthian and Bright (2004) described quercetin, a flavonoid phytoestrogen, also to ameliorate EAE.
The capacity of various flavonoids to inhibit phagocytosis in vitro correlates with their antioxidative potency, and is in line with the requirement of ROS for myelin phagocytosis by macrophages (Hendriks et al, 2003) . Moreover, oral administration of luteolin effectively reduces clinical symptoms in chronic EAE .
Curcumin. Curcumin (diferuloyl methane) is a naturally occurring compound isolated from the rhizomes of the plant Curcuma longa and frequently used as a yellow pigment in curry. Curcuma longa has an extensive history in traditional medicine and dietary use in Asian countries (Eigner & Scholz, 1999) . The food additive curcumin is a natural product and its safety was supported by the nontoxic consumption of up to 110 mg/day in humans and up to 5 g/day in rats (Commandeur & Vermeulen, 1996) . Curcumin has many biological effects, including antiinflammatory, antioxidant, anticarcinogenic, antiviral and anti-infectious activity (Joe et al, 2004) . It protects against H 2 O 2 -induced oxidative stress in renal epithelial cells (Cohly et al, 1998) and inhibits the production of superoxide radicals, H 2 O 2 and NO by macrophages (Joe & Lokesh, 1994; van Meeteren et al, 2004) and astrocytes (Soliman & Mazzio, 1998) . Although antioxidative effects cannot be excluded, the inhibitory effect of curcumin on clinical and pathological symptoms in murine EAE were attributed to blocking of IL-12 signalling through the Janus kinase-STAT pathway in T cells (Natarajan & Bright, 2002) . In addition, in a mouse model of Alzheimer-like pathology, curcumin was found to decrease inflammation and oxidative damage in the brain (Lim et al, 2001 ).
Polyunsaturated fatty acids (PUFAs)
From the human diet, LA and a-linolenic acid (LNA; 18:n-3) are required as substrates for the synthesis of the essential n-6 and n-3 long-chain fatty acids (Figure 1 ). It has been established that changes in dietary fat intake alter PUFA incorporation in cell membranes (Clandinin et al, 1991) , where these compounds have different effects. They may induce immunosuppression through their actions on the arachidonic acid (AA; 20:4n-6) pathway (Meydani, 1996) . Membrane incorporation of PUFAs may change cellular susceptibility to lipid peroxidation, alter membrane fluidity, receptor function, enzyme activity, and influence the production of lipid mediators (Wu & Meydani, 1998) . At the intracellular level, PUFA incorporation may change the receptor-mediated stimulation of gene products or the transport of gene products from the nucleus (Clandinin et al, 1991) .
PUFAs in experimental models of MS Oral administration of essential fatty acids (EFA) suppressed EAE (Mertin & Stackpoole, 1978) . This effect could be abolished by indomethacin, indicating prostaglandins (PGs) as mediators of this effect (Mertin & Stackpoole, 1978) . In addition, clinical signs of EAE could be abrogated by oral administration of GLA and LA-rich oils (Harbige et al, 1995) . In another study, oral supplementation with n-6 fatty acid GLA from Borago officinalis ameliorated both acute and chronic disease in EAE (Harbige et al, 2000) . This was associated with increased DGLA and AA in the cell membrane, gene transcription, production of prostaglandin E 2 (PGE 2 ) and secretion of TGF-b1. The increased levels of PGE 2 were associated with an altered balance of TH1 and TH2-type cytokines, thus preventing T-cell-mediated autoimmune disease (Harbige et al, 2000) . Intraperitoneal administration of a mixture of essential fatty acids, containing LA (n-6) and LNA (n-3), improved biochemical and cognitive functions in EAE rats by improving neuronal communication at brain synaptosomes as compared to nontreated EAE animals (Yehuda et al, 1997) .
Immune modulation and CNS cell function As precursors for inflammatory mediators, for example, PGs, tromboxanes (TXs) and leukotrienes, PUFAs can affect the immune response. The fatty acids of the n-3 family give rise to PGs of the '3' series, while those from the n-6 family give rise to the '1' and '2' series ( Figure 1) . As a result of changes in this eicosanoid production, PUFAs can affect cytokine expression (Grimble, 1998) . N-3 PUFAs may suppress proinflammatory TNF-a and IL-1 production and actions, while n-6 PUFAs have the opposite effect. Indeed, patients with autoimmune diseases, such as rheumatoid arthritis, inflammatory bowel disease and asthma, responded well to supplementation with long-chain n-3 fatty acids EPA and DHA by decreasing disease-associated elevated levels of cytokines (Simopoulos, 2002) . In addition, fish oil supplementation of newly diagnosed MS patients increased the plasma phospholipid n-3 fatty acids and decreased the n-6 fatty acids, resulting in significant reduction of exacerbations and the EDSS clinical score (Nordvik et al, 2000) . Apart from their immunomodulatory effects, these compounds may change the PUFA membrane profile of cells within the CNS, thereby changing brain cell activity.
n-6 PUFAs. Dietary oils derived from plants and seeds are the main source of n-6 PUFAs. After cellular uptake of LA, elongation and desaturase enzyme activity can produce the longer-chain fatty acids, for example, GLA, DGLA and arachidonic acid (AA; 20:4n-6). During pathological conditions, the release of AA from the cell membrane by phospholipase A 2 activity will be increased, giving rise to proinflammatory PGs and TXs of the '2' series, that is, PGE 2 and tromboxane A 2 (TXA 2 ), while DGLA is a precursor of PGs of the '1' series harbouring anti-inflammatory properties.
In vitro n-6 PUFAs can alter the function of oligodendrocytes by affecting their membrane composition (Soliven & Wang, 1995) . For instance, membrane depolarisation affects protein phosphorylation of myelin basic protein in oligodendrocytes, an important event in myelination (Takeda & Soliven, 1997) .
n-3 PUFAs. EPA and DHA both belong to the group of n-3 PUFAs. Membrane DHA originates from dietary DHA and by conversion of dietary LNA with EPA as an intermediate product (Alessandri et al, 2003) . However, DHA can function as a source of EPA as well through retro-conversion. Subsequently, EPA can be oxygenated to various eicosanoid metabolites such as PGE 3 , PGF 3 and TXA 3 (Youdim et al, 2000) . Fish oil and oily fish are dietary sources both rich in n-3 PUFAs. High dietary LNA increases the LNA, but not the DHA contents in brains of suckling rats (Bowen & Clandinin, 2000) . Thus, when increased DHA in the brain is required, DHA itself, and not LNA, should be administered.
Dietary supplementation with a mixture of EPA and DHA could reduce cytokine secretion and eicosanoid production in peripheral blood mononuclear cells of relapsing-remitting MS patients (Gallai et al, 1995) .
By competing with AA for the same metabolising enzymes, EPA and DHA can prevent the formation of leukotriene and PGE 2 synthesis in vitro (Needleman et al, 1979; Lee et al, 1988) . It was also shown that OLN-93 oligodendrocytes enriched with DHA and exposed to H 2 O 2 were more susceptible to apoptosis than controls (Brand et al, 2001 ). This study underlines that membrane lipid composition is critical in either promoting or preventing apoptotic cell death (Brand et al, 2001) . Moreover, increased incorporation of very long PUFAs into the cell membrane may result in increased susceptibility to lipid peroxidation (Song et al, 2000) . High tissue and plasma DHA levels in rats due to the ingestion of DHA-containing oil enhanced membrane susceptibility to lipid peroxidation and disrupted the antioxidant system. Since this was accompanied by a reduction of a-tocopherol levels appropriate vitamin E, supplementation should be considered in that case.
Cholesterol and statins
Statins have important biologic effects independent from their cholesterol-reducing properties that may be beneficial in neurodegenerative diseases and MS (Stüve et al, 2003a) . Several studies revealed statins to ameliorate clinical signs of disease in EAE (Stanislaus et al, 2002; Youssef et al, 2002; Greenwood et al, 2003; Floris et al, 2004) . The cholesterollowering effect of statins is regulated through inhibition of b-hydroxy-b-methylglutaryl-CoA (HMG-CoA) reductase. This enzyme is involved in cholesterol synthesis and converts HMG-CoA to L-mevalonate. Through inhibition of HMG-CoA reductase, statins prevent numerous biological activities downstream of L-mevalonate (Stüve et al, 2003b) . Statins may also inhibit T-cell entry into the CNS, inhibit T-cell activation and suppress secretion of numerous inflammatory mediators. Moreover, lovostatin treatment of EAE rats inhibits macrophage infiltration (Floris et al, 2004) and simvastatin treatment is beneficial in relapsing-remitting MS (Vollmer et al, 2004) . Statins may be of therapeutic interest since they can be given orally with a very good safety record (Polman & Uitdehaag, 2003) . Since statins ameliorate MS through immunomodulatory activity, it seems interesting to explore whether dietary compounds also interfere with the cholesterol synthesis.
Curcumin could modulate cholesterol levels in several experimental models of atherosclerosis (Soudamini et al, 1992; Ramirez-Tortosa et al, 1999) . Aside from inhibition of lipid peroxidation, curcumin also decreased cholesterol levels in both the serum and brain tissue of mice (Soudamini et al, 1992) . In rats, curcumin significantly decreased the total and very low-density lipoprotein (VLDL) and LDL cholesterol plasma concentrations (Kamal-Eldin et al, 2000) .
In healthy human subjects, curcumin significantly decreased serum lipid peroxide levels, increased high-density lipoprotein cholesterol and decreased total serum cholesterol . The underlying mechanism may involve reduced intestinal uptake of cholesterol (Kamal-Eldin et al, 2000) . It has been established that tocotrienol, a vitamin E isoform, also has hypocholesterolaemic properties through a mechanism different from HMG-CoA reductase inhibition (Theriault et al, 1999) .
Dietary compounds targeting different pathomechanisms in MS
a-Lipoic acid and its reduced form DHLA were shown to inhibit T-cell migration into the spinal cord and suppressed clinical signs in murine EAE (Marracci et al, 2002) . This finding indicates that these dietary compounds can interfere with inflammatory mechanisms. In addition, flavonoids and curcumin were shown to posses anti-inflammatory properties in EAE models (Natarajan & Bright, 2002; Hendriks et al, 2004) , suggesting these compounds to have the ability to reduce MS disease activity. Furthermore, dietary fatty acids have immunoregulatory activity and the inflammatory process in autoimmune disease may be an important mechanistic target for these compounds to modulate disease activity (Harbige, 1998) .
Due to their free radical scavenging, metal chelation and radical chain reaction-breaking properties, nonenzymatic antioxidants, for example, vitamin C, vitamin E, thiol-based antioxidants, flavonoids and curcumin, are important in prevention of oxidative stress. Moreover, dietary compounds, for example, flavonoids, curcumin, NAC and vitamin E, can protect neuronal cells against glutamateinduced excitotoxicity (Kobayashi et al, 2000; Sen et al, 2000; Mazzio et al, 2001 ). In conclusion, dietary antioxidants and fatty acids may influence the disease process in MS by reducing immune-mediated inflammation, oxidative stress and excitotoxic damage.
CNS bioavailability of dietary antioxidants and PUFAs
Central availability of dietary compounds or their metabolites is a main obstacle for their use in nutritional therapy of neurodegenerative diseases, including MS. When dietary products comprising antioxidants and/or PUFAs are considered for brain diseases, aspects of biotransformation and CNS availability need to be addressed.
While many compounds have a limited passage through the BBB, the brain levels of the low-molecular-weight members of the antioxidant network, for example, vitamin C and E and GSH, are under strong homeostatic regulation. NAC, the precursor molecule of GSH, cannot cross the BBB after exogenous administration (Gilgun-Sherki et al, 2002) . On the other hand, a-lipoic acid that is readily absorbed from the diet does cross the BBB (Packer et al, 1997) .
Flavonoid antioxidants are present in food as glycosides and the sugar moiety may facilitate their bioavailability in humans (Hollman et al, 1999) . But data on the bioavailability of flavonoids in the brain and other tissues are very scarce (Manach et al, 2004) . Two studies demonstrated the presence of flavonoids in the brain tissue of mice (Abd El Mohsen et al, 2002) and rats (Datla et al, 2001 ) after oral administration. However, data on flavonoid concentrations in human brains are not available.
Curcumin is a lipid-soluble compound that easily penetrates into the cytoplasm and accumulates in membranous structures such as the plasma membrane, the endoplasmic reticulum and the nuclear envelope (Jaruga et al, 1998) . From studies in mice, it became clear that curcumin is absorbed in the intestine and subsequently metabolised. Biotransformation of curcumin takes place through reduction and glucuronidation, and indeed traces of curcumin could be found in the murine brain (Pan et al, 1999) .
Supplementation with long-chain PUFAs can change blood lipid and fatty acid profiles in healthy subjects (Laidlaw & Holub, 2003) . Brain bioavailability of PUFAs has been studied extensively in rodents. The potential sources of lipids in the nervous system are both in situ synthesis and uptake from plasma. From studies in rat, it became clear that the brain is clearly sensitive to alteration of dietary lipid intake (Foot et al, 1982) . Moreover, myelin formation in the rat brain can be accelerated by dietary lipids (Salvati et al, 1996) . Postnatal deficiency of essential fatty acids reduces the mRNA levels of specific oligodendrocyte myelin proteins in the mouse brain (DeWille & Farmer, 1992) . These findings support the rationale for supplementation with specific PUFAs to support (re)myelination.
Conclusion
Research on the possible relationship between diet and MS is important and several problems should be tackled. MS is the most frequent neurodegenerative disease in young adults and is currently diagnosed according to the McDonald criteria (Dalton et al, 2002) by using magnetic resonance imaging (MRI) evidence of dissemination of lesions in time and space. MRI is an almost indispensable outcome measure in clinical trials (Van Oosten et al, 2004 ) that makes clinical research on the effect of dietary compounds complex and expensive. Measuring PUFA and antioxidant levels in different body compartments will be an important strategy to select patients for complementary treatment. But it will remain difficult to discriminate between abnormal physical values present before the disease and those that are secondary to the disease. Over the years, evidence has built up on the impaired antioxidant status of MS patients and the potential beneficial role of dietary antioxidant supplementation in reducing the severity and duration of attacks. Deficiencies in PUFA levels have been observed in blood and various other tissues of MS patients. Besides the immunosuppressive effects of PUFAs, their membrane incorporation may also influence the function of cells within the CNS. Moreover, there are accumulating data from experimental models demonstrating the important role of antioxidants and PUFAs on immunopathological mechanisms in MS. In our view, the present data warrant further controlled clinical studies with antioxidants and PUFAs to substantiate the relevance of these dietary compounds in the treatment of MS.
